Page 96 - Read Online

Schwarzenbach et al. Cancer Drug Resist 2019;2:271-96 I http://dx.doi.org/10.20517/cdr.2019.010 Page 295

135. Fuss JO, Tainer JA. XPB and XPD helicases in TFIIH orchestrate DNA duplex opening and damage verification to coordinate repair
with transcription and cell cycle via CAK kinase. DNA Repair (Amst) 2011;10:697-713.
136. Zhao H, Yu X, Ding Y, Zhao J, Wang G, et al. MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting
ERCC2. Oncotarget 2016;7:53254-68.
137. Bruchim I, Werner H. Targeting IGF-1 signaling pathways in gynecologic malignancies. Expert Opin Ther Targets 2013;17:307-20.
138. Zhang Y, Huang S, Guo Y, Li L. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R. Biomed Pharmacother
2018;106:1357-63.
139. Stuckrath I, Rack B, Janni W, Jager B, Pantel K, et al. Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a
are associated with lymph node metastasis and receptor status of breast cancer patients. Oncotarget 2015;6:13387-401.
140. Wilczyński M, Zytko E, Szymanska B, Dzieniecka M, Nowak M, et al. Expression of miR-146a in patients with ovarian cancer and its
clinical significance. Oncol Lett 2017;14:3207-14.
141. Benson EA, Skaar TC, Liu Y, Nephew KP, Matei D. Carboplatin with decitabine therapy, in recurrent platinum resistant ovarian cancer,
alters circulating mirnas concentrations: a pilot study. PLoS One 2015;10:e0141279.
142. Schwarzenbach H. The clinical relevance of circulating, exosomal miRNAs as biomarkers for cancer. Expert Rev Mol Diagn
2015;15:1159-69.
143. Kuhlmann JD, Chebouti I, Kimmig R, Buderath P, Reuter M, et al. Extracellular vesicle-associated miRNAs in ovarian cancer - design
of an integrated NGS-based workflow for the identification of blood-based biomarkers for platinum-resistance. Clin Chem Lab Med
2018; doi: 10.1515/cclm-2018-1048.
144. Wiedemeyer WR, Beach JA, Karlan BY. Reversing platinum resistance in high-grade serous ovarian carcinoma: targeting BRCA and
the homologous recombination system. Front Oncol 2014;4:34.
145. Fell VL, Schild-Poulter C. The Ku heterodimer: function in DNA repair and beyond. Mutat Res Rev Mutat Res 2015;763:15-29.
146. Choi YE, Meghani K, Brault ME, Leclerc L, He YJ, et al. Platinum and PARP inhibitor resistance due to overexpression of MicroRNA-622
in BRCA1-mutant ovarian cancer. Cell Rep 2016;14:429-39.
147. Yu X, Chen Y, Tian R, Li J, Li H, et al. MiRNA-21 enhances chemoresistance to cisplatin in epithelial ovarian cancer by negatively
regulating PTEN. Oncol Lett 2017;14:1807-10.
148. Chan JK, Blansit K, Kiet T, Sherman A, Wong G, et al. The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian
cancer. Gynecol Oncol 2014;132:739-44.
149. Liu S, Fang Y, Shen H, Xu W, Li H. Berberine sensitizes ovarian cancer cells to cisplatin through miR-21/PDCD4 axis. Acta Biochim
Biophys Sin (Shanghai) 2013;45:756-62.
150. Liu W, Wang S, Zhou S, Yang F, Jiang W, et al. A systems biology approach to identify microRNAs contributing to cisplatin resistance
in human ovarian cancer cells. Mol Biosyst 2017;13:2268-76.
151. Yu PN, Yan MD, Lai HC, Huang RL, Chou YC, et al. Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer
cells. Int J Cancer 2014;134:542-51.
152. Han X, Zhen S, Ye Z, Lu J, Wang L, et al. A feedback loop between miR-30a/c-5p and DNMT1 mediates cisplatin resistance in ovarian
cancer cells. Cell Physiol Biochem 2017;41:973-86.
153. Liu J, Wu X, Liu H, Liang Y, Gao X, et al. Expression of microRNA-30a-5p in drug-resistant and drug-sensitive ovarian cancer cell lines.
Oncol Lett 2016;12:2065-70.
154. Srivastava AK, Han C, Zhao R, Cui T, Dai Y, et al. Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of
ovarian cancer stem cells. Proc Natl Acad Sci U S A 2015;112:4411-6.
155. Liu L, Guo J, Yu L, Cai J, Gui T, et al. MiR-101 regulates expression of EZH2 and contributes to progression of and cisplatin resistance
in epithelial ovarian cancer. Tumour Biol 2014;35:12619-26.
156. Li H, Xu H, Shen H, Li H. MicroRNA-106a modulates cisplatin sensitivity by targeting PDCD4 in human ovarian cancer cells. Oncol
Lett 2014;7:183-8.
157. Rao YM, Shi HR, Ji M, Chen CH. MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells. J Huazhong
Univ Sci Technolog Med Sci 2013;33:567-72.
158. Kong F, Sun C, Wang Z, Han L, Weng D, et al. MiR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-
apoptotic Bcl-2 antagonist killer 1. J Huazhong Univ Sci Technolog Med Sci 2011;31:543.
159. Li N, Yang L, Wang H, Yi T, Jia X, et al. MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human
Ovarian Cancer A2780 Cells. PLoS One 2015;10:e0128886.
160. Zhang X, Huang L, Zhao Y, Tan W. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting
X-linked inhibitor of apoptosis (XIAP) directly. Acta Biochim Biophys Sin (Shanghai) 2013;45:995-1001.
161. Yang L, Li N, Wang H, Jia X, Wang X, et al. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation
of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance. Oncol Rep 2012;28:592-600.
162. Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, et al. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol
Oncol 2008;111:478-86.
163. Zong C, Wang J, Shi TM. MicroRNA 130b enhances drug resistance in human ovarian cancer cells. Tumour Biol 2014;35:12151-6.
164. Chen S, Jiao JW, Sun KX, Zong ZH, Zhao Y. MicroRNA-133b targets glutathione S-transferase pi expression to increase ovarian cancer
cell sensitivity to chemotherapy drugs. Drug Des Devel Ther 2015;9:5225-35.
165. Li X, Chen W, Jin Y, Xue R, Su J, et al. MiR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple
anti-apoptotic genes. Biochem Pharmacol 2019;161:98-112.